Drug Approval | April 28, 2025
Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
The biosimilar Ustekinumab has been developed and manufactured by the company
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated
